Back to Authors

Willey, Richard G.

A5108930846 | I145311141

Mayo Clinic

Alnylam Pharmaceuticals (United States)

Citations 5

Long-Term Efficacy and Safety of Lumasiran in Patients with Primary Hyperoxaluria Type 1: Final Analysis of the ILLUMINATE-A Trial

Journal of the American Society of Nephrology | October 28, 2024 | Volume: 35 | Issue: 10S | Pages: No page available

10.1681/asn.2024vkc16faf

Natural History of Advanced Primary Hyperoxaluria Type 1: A Retrospective Study

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 572-572

10.1681/asn.20233411s1572a

Lumasiran for Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 24-Month Analysis of the Phase 3 ILLUMINATE-C Trial

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 566-566

10.1681/asn.20233411s1566b

Lumasiran for Patients With Primary Hyperoxaluria Type 1 and Impaired Kidney Function: 12-Month Analysis of the Phase 3 ILLUMINATE-C Trial

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 33 | Issue: 11S | Pages: 416-416

10.1681/asn.20223311s1416a

ILLUMINATE-C, a Single-Arm, Phase 3 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 and CKD Stages 3b-5, Including Those on Hemodialysis

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: B2-B2

10.1681/asn.20213210s1b2a